A Phase I Study of LY3023414 in Patients with Advanced Cancer

Full Title

A Phase 1 First-in-Human Dose Study of LY3023414 in Patients with Advanced Cancer


The purpose of this study is to find the highest dose of an investigational drug called LY3023414 in patients with advanced solid tumors that are not responding to standard treatments. LY3023414 is designed to work by blocking the activity of two proteins known to fuel cancer growth: PI3 kinase (PI3K) and mTOR. LY3023414 is a capsule that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor that is not responding to standard therapy.
  • At least 3 weeks must pass since completion of prior therapies and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Anna Varghese at 646-888-4308.